Overview

Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg

Status:
COMPLETED

Trial end date:
2025-10-06

Target enrollment:

Participant gender:

Summary

An Open Label, Balanced, Randomized, Single dose, Two treatment, Two sequence, Two period, two way crossover, Oral Bioequivalence Study of test product of Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet and Reference product of Synjardy XR tablets 25mg/1000mg in Healthy, adult, human Subjects Under fed Condition.

Phase:

PHASE1

Details

Lead Sponsor:

Humanis Saglk Anonim Sirketi

Treatments:

empagliflozin